{"id":"W2055235037","doi":"10.1016/s1470-2045(13)70411-x","title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":386,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Oncology; Population; Pertuzumab; Cyclophosphamide; Chemotherapy; Surgery; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002902753,0.003012743,0.003466259,0.0005485357,0.0006642403,0.001618227,0.001214802,0.002638284,0.01573076],"category_scores_gemma":[0.002774293,0.001123957,0.002971472,0.0006260817,0.002111041,0.001891475,0.0008813391,0.005380075,0.002626917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001504785,"about_ca_system_score_gemma":0.002389364,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001645587,"about_ca_topic_score_gemma":0.003587488,"domain_scores_codex":[0.9986635,0.0008098973,0.0000594453,0.0001782729,0.00007525535,0.0002136824],"domain_scores_gemma":[0.9986437,0.000372126,0.0002455811,0.0001311704,0.000058187,0.0005492497],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9881521,0.002560438,0.0001591288,0.0004001691,0.0003814218,0.00001828907,0.0000370339,0.0003136721,0.0008986545,0.00008954766,0.000885429,0.006104088],"study_design_scores_gemma":[0.9770733,0.02168532,0.0003179987,0.00002134031,0.0001273551,0.00001333474,0.00001016914,0.0001528336,0.00009225088,0.000137336,0.0003600343,0.0000087557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9451752,0.0059107,0.00249766,0.002717505,0.001564461,0.02736668,0.005631763,0.0005317992,0.008604182],"genre_scores_gemma":[0.9320534,0.004234921,0.005419084,0.003495436,0.0006994734,0.03791285,0.004591351,0.0001298001,0.01146372],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01573076,"threshold_uncertainty_score":0.05262464,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1888122349117266,"score_gpt":0.5311267806640083,"score_spread":0.3423145457522817,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}